CTMX CYTOMX THERAPEUTICS INC Business Restructuring 8-K Filing 2025 - Workforce Reduction CytomX Therapeutics plans to restructure its business by reducing its workforce by about 40%, primarily affecting general and administrative roles, to focus on CX-2051 and extend its cash runway into mid-2026, with expected restructuring costs of $5-$6 million.Get access to all SEC 8-K filings of the CYTOMX THERAPEUTICS INC